Jenscare Announces 2025H1 Interim Results

BEIJING, Aug. 31, 2025 /PRNewswire/ -- Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company dedicated to interventional treatment for structural heart diseases, achieved key milestones in its product portfolio and just announced its interim results for 2025H1.

Business Highlights: Big Movement in Commercialization, Registration and Clinical

LuX-Valve Series, TTVR system

In China, the multicenter clinical trial for NMPA approval has entered long-term follow-up phase, demonstrating excellent results. The randomized controlled trial (RCT) of optimized medical therapy (OMT) has completed subject enrollment. The registration application has received acceptance from NMPA, entering registration stage.

In Europe, LuX-Valve Plus has completed 6-month follow-up of TRINITY study, its clinical trial for CE Marking and is currently under registration review.

In U.S., the IDE Early Feasibility Study (EFS) of LuX-Valve Plus has ...